# A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

> **NCT07241767** · PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
- **DRUG:** FH-006 ; SHR-1316 ; BP102
- **DRUG:** FH-006; SHR-1316 ; SHR-8068

## Key facts

- **NCT ID:** NCT07241767
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-12
- **Primary completion:** 2027-11
- **Final completion:** 2028-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241767, "A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07241767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*